Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
Angelos Stergiou
About SELLAS Life Sciences Group
Dr. Angelos M. Stergiou, MD, ScD h.c. is the CEO and Vice Chairman
of SELLAS Life Sciences Group, which he founded with th...
The points below will help you learn more about SELLAS Life
Sciences Group and what the company is contributing to the wor...
To learn more about the work of SELLAS Life Sciences Group or Dr.
Angelos Stergiou, visit www.sellaslifesciences.com
Also ...
Upcoming SlideShare
Loading in …5
×

Angelos Stergiou - About SELLAS Life Sciences Group

440 views

Published on

Angelos Stergiou, MD is the Vice Chairman, Chief Executive Officer and Angelos Stergiou also Founder of SELLAS Life Sciences Group.

Published in: Business
  • Be the first to comment

  • Be the first to like this

Angelos Stergiou - About SELLAS Life Sciences Group

  1. 1. Angelos Stergiou About SELLAS Life Sciences Group
  2. 2. Dr. Angelos M. Stergiou, MD, ScD h.c. is the CEO and Vice Chairman of SELLAS Life Sciences Group, which he founded with the intention to give back to humanity through clinical research, discovery and drug development. In recent news, Dr. Angelos Stergiou and SELLAS Life Sciences Group have received increasing media coverage as the progression of the WT1 neoepitome immunotherapeutic anti-cancer treatment and vaccine continues to yield promising results.
  3. 3. The points below will help you learn more about SELLAS Life Sciences Group and what the company is contributing to the world: • SELLAS Life Sciences Group. As a leading international biopharmaceutical company, SELLAS Life Sciences focuses on advancing various cancer therapies and developing diverse cancer programs. The company seeks to improve the lives of patients everywhere by commercializing cutting-edge cancer therapeutics. • WT1 Neoepitope Immunotherapy. Named for the WT1 antigen – one of the most common antigens found in malignancies – the WT1 anti-cancer treatment, called galinpepimut-S, consists of four synthetically heteroclitically modified peptide chains that are designed to induce patient immune response against the WT1 antigen. As of 2016, trial phases have shown promising survival benefits.
  4. 4. To learn more about the work of SELLAS Life Sciences Group or Dr. Angelos Stergiou, visit www.sellaslifesciences.com Also connected with Angelos Stergiou through social profiles: https://twitter.com/drstergiou www.scoop.it/t/angelos-stergiou https://plus.google.com/116965580440240268259 www.facebook.com/Angelos-Stergiou-1813027965638555/

×